GD2IL18CART

DRUG2 trials

Sponsors

Universitaet Muenster

Conditions

Advanced breast cancerEwing sarcomaNeuroblastomaOsteosarcoma

Phase 1

A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers

RecruitingCTIS2022-501725-21-00

Universitaet MuensterAdvanced breast cancer, Ewing sarcoma, Neuroblastoma +1

Start: 2024-04-12Target: 48Updated: 2025-10-17

Long-term follow-up of patients treated with GD2IL18CART

RecruitingCTIS2025-521497-34-00

Universitaet MuensterAdvanced breast cancer, Ewing sarcoma, Neuroblastoma +1

Start: 2025-10-06Target: 20Updated: 2025-09-02

Related Papers

Abstract IA015: GD2-specific CAR T cell therapies for pediatric solid cancers

Cancer Research2024-09-05

Abstract 6328: Preclinical development of CAR T cells with antigen-inducible IL-18 enforcement to treat GD2-positive solid cancers

Cancer Research2024-03-22